Clinical review report: Tapentadol hydrochloride extended-release tablet (Nucynta extended-release) (Paladin labs inc.)
The objective of this review is to perform a systematic review of the beneficial and harmful effects of tapentadol hydrochloride extended-release tablets (Nucynta Extended-Release) 100 mg to 250 mg twice a day for the management of pain severe enough to require daily, continuous, long-term opioid tr...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, October 2018
|
| Edition: | Final |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references